Analyst attention rises: Social media chatter around Agios Pharmaceuticals has centered on the potential for following select trader insights, with participants noting significant gains from prior recommendations on the stock.
Community engagement grows: Discussions highlight the formation of dedicated groups for shareholders to exchange updates and market observations, reflecting ongoing interest in collaborative analysis of recent price action.
Cautious optimism prevails: Overall, the tone remains measured as users stress the importance of monitoring developments without committing to specific directional bets.
Note: This discussion summary was generated from an AI condensation of post data.
Agios Pharmaceuticals Insider Trading Activity
Agios Pharmaceuticals insiders have traded $AGIO stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 2 sales selling 32,940 shares for an estimated $1,016,447.
- BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 2 sales selling 19,068 shares for an estimated $661,850.
- JAMES WILLIAM BURNS (Chief Legal Officer) sold 3,280 shares for an estimated $113,848
- TSVETA MILANOVA (Chief Commercial Officer) sold 3,262 shares for an estimated $113,224
- CECILIA JONES (Chief Financial Officer) sold 3,141 shares for an estimated $109,024
- KRISHNAN VISWANADHAN (Chief Corp Dev & Strategy) sold 2,959 shares for an estimated $102,706
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenues of $44.7M in Q2 2026. This is an increase of 259.25% from the same period in the prior year.
You can track AGIO financials on Quiver Quantitative's AGIO stock page.
You can access data on AGIO stock through the Quiver Quantitative API.
Agios Pharmaceuticals Congressional Stock Trading
Members of Congress have traded $AGIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 08/20.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Agios Pharmaceuticals Hedge Fund Activity
We have seen 127 institutional investors add shares of Agios Pharmaceuticals stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LYNX1 CAPITAL MANAGEMENT LP added 2,531,944 shares (+3179.9%) to their portfolio in Q1 2026, for an estimated $85,655,665
- MPM BIOIMPACT LLC removed 1,306,261 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $48,475,345
- D. E. SHAW & CO., INC. added 1,269,819 shares (+69.1%) to their portfolio in Q2 2026, for an estimated $47,122,983
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,256,080 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $46,613,128
- TCG CROSSOVER MANAGEMENT, LLC removed 1,181,841 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $39,981,681
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,147,381 shares (+815.6%) to their portfolio in Q2 2026, for an estimated $42,579,308
- UBS GROUP AG added 853,291 shares (+643.8%) to their portfolio in Q2 2026, for an estimated $31,665,629
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Agios Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 7 analysts offer price targets for $AGIO in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Gregory Renza from Truist Securities set a target price of $41.0 on 07/07/2026
- Alec Stranahan from B of A Securities set a target price of $46.0 on 07/07/2026
- Luca Issi from RBC Capital set a target price of $32.0 on 07/07/2026
- Tessa Romero from JP Morgan set a target price of $31.0 on 06/11/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $50.0 on 04/20/2026
- Salveen Richter from Goldman Sachs set a target price of $32.0 on 04/01/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
